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Abstract: Omalizumab is marketed for chronic severe asthma patients who are allergic to perennial
allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe
asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were
treated with Omalizumab according to the dosing table. For each patient with asthma due to
seasonal allergens, we recruited the next two consecutive patients with asthma due to perennial
allergens. The dose of oral methyl prednisolone (MP) was tapered at a rate of 2 mg every two
weeks after the start of treatment with omalizumab depending on tolerance. At each monthly visit,
a forced spirometry and fractional exhaled nitric oxide (FeNO) measurement were performed and the
accumulated monthly MP dose was calculated. At entry, there were no differences between groups in
terms of gender, body mass index or obesity, year exacerbation rate, monthly dose of MP, FeNO and
blood immunoglobuline E (IgE) values, or spirometry (perennial: FVC: 76%; FEV1: 62%; seasonal:
FVC: 79%; FEV1: 70%). The follow-up lasted 76 weeks. One patient in each group was considered
a non-responder. Spirometry did not worsen in either group. There was a significant intragroup
reduction in annual exacerbation rate and MP consumption but no differences were detected in the
intergroup comparison. Omalizumab offered the same clinical benefits in the two cohorts regardless
of whether the asthma was caused by a seasonal or a perennial allergen. These results strongly
suggest that allergens are the trigger in chronic asthma but that it is the persistent exposure to IgE
that causes the chronicity.
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1. Introduction
Omalizumab has been the only monoclonal antibody marketed for treatment of severe allergic
asthma for more than 10 years. It was first included in Global Initiative for asthma (GINA) guidelines
in November 2006 [1] and became commercially available in Spain in 2007. Initially, the criteria
for administering the drug were: age over 12, severe or inadequately controlled allergic asthma
due to at least one perennial allergen, maximum weight 150 kg, and blood immunoglobuline E (IgE)
concentration between 30 and 700 IU/mL. The maximum monthly calculated dose was 750 mg [2,3].
Since then, age (reduced to six years), IgE concentration (increased to ≥30–1500 kU/L) and total
dose of omalizumab (now ≤1200 mg) have been modified, and chronic urticaria has been included
as an indication. Omalizumab has shown clinical efficacy and effectiveness in GINA step V asthma
patients [4–9]. In addition, some studies have shown its efficacy in non-allergic asthma [4,6].
The term “entopy” has been introduced to refer to patients with localized expression of certain
allergic characteristics [10] and some authors have proposed that omalizumab may have a wider range
of possible prescriptions.
An issue that has never been discussed in the literature is whether omalizumab is equally effective
in patients with severe chronic asthma caused by seasonal allergens as in patients with asthma caused
by perennial allergens. We designed a pilot study to evaluate whether the effectiveness of omalizumab
treatment in chronic severe asthma depends on the perennial or seasonal nature of the allergen.
2. Results
The demographic data at entry are shown in Table 1. Ten patients were included in the seasonal
allergen group and 20 in the perennial group. One patient of each group was considered non-responder
(in the seasonal group the patient was the one allergic to pollen of Parietaria), and so the comparison
was made between 9 patients from the seasonal group and 19 from the perennial group. There were
no differences in year exacerbation rate, age (perennial: 54 ± 15.8 years; seasonal: 50 ± 17.1; p = 0.56)
body mass index (BMI), eosinophils, or fractional exhaled nitric oxide (FeNO) (Table 1). Applying
the World Health Organization (WHO) classification, there were no differences in overweight (57.9%
perennial and 44.4% seasonal; p = 0.698) or obesity (36.8% perennial and 11.1% seasonal; p = 0.214).
IgE concentrations were slightly higher in seasonal allergen patients, although the difference was not
statistically significant. Pulmonary function tests (PFTs) were slightly better in the seasonal group (with
FEV1 around 200 mL higher), although the difference was not statistically significant. The omalizumab
dose and methyl-prednisolone (MP) intake were the same in the two groups. The follow-up lasted
76 weeks. The allergen sensitization is described in Table 2.
Table 1. Demographic data at entry of the whole group and the two subgroups.
All Perennial Seasonal
n % n % n %
Male/Female 9/19 32.1/67.9 8/19 42.1/57.9 1/9 11.1/88.9
Median IQR Median IQR Median IQR
Exacerbation (year/rate) 2.67 3.17 2.67 2.67 2.67 4.00
Omalizumab dose 300 450 300 300 300 300
Corticoids 120 224 120 224 120 168
IgE 178.5 254.8 138 173.1 229 184
FeNO 15 32 14 25 17 26
Mean SD Mean SD Mean SD
Body Mass Index 27.43 5.75 27.68 4.25 26.91 8.39
EoS (%) 5.31 3.53 5.2 3.79 5.29 2.93
EoS 429.29 313.83 410.00 328.67 440.00 274.10
FVC 2.69 0.78 2.71 0.90 2.67 0.52
FVC% 77.21 17.99 76.32 20.38 79.11 12.35
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Table 1. Cont.
All Perennial Seasonal
Mean SD Mean SD Mean SD
FEV1 1.71 0.59 1.65 0.63 1.85 0.49
FEV1% 64.93 20.66 62.21 22.29 70.67 16.36
FEV1/FVC% 63.43 13.34 60.74 13.08 69.11 12.75
FeNO: fraction exhaled of nitric oxide. EoS: eosinophils; FEV1: forced expiratory volume in one second; FVC: forced
vital capacity; IQR: interquartile range; p-value was not significant for all the variables compared.
Table 2. Allergen detected by skin prick test.
Perennial allergens (n = 20) Seasonal allergens (n = 10)
House dust mites 13 Grass pollens 2
Moulds 2 Grass Pollens + cat epithelium 1
House dust mites + cat and dog epithelium + grass pollen 2 Cupressus Pollens + cat epithelium 1
House dust mites + grass pollen 1 Grass Pollens + cat and dog epithelium 2
House dust mites + cat epithelium + moulds 1 Grass Pollen + bird feathers 1
House dust mites + cat epithelium + grass pollen + moulds 1 Grass Pollen + rabbit epithelium 1
Grass Pollen + house dust mites 1
Parietaria Pollen + house dust mites 1
2.1. Changes in the Number of Exacerbations
Although we compared the number of exacerbations during the 76 weeks previous to omalizumab
treatment with the 76-week follow-up, data are given as annual exacerbation rates. Both groups showed
a statistically significant decrease (Figure 1A–C) and no differences were observed between them
(p = 0.678).
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Figure 1. This figure shows the decrease i the ye r exacerbation rate of the whole group (A)
(* p < 0.001); per nnial group (B) (** p = 0.004) and seasonal grou (C) (*** p = 0.020). Lower box
hinge: percentile 25. Upper box hinge: percentile 75. Line inside the box: percentile 50 (median).
Outside value definition: Value lower than percentile 25 − 1.5 × (percentile 75 − percentile 25) or
value higher than percentile 75 + 1.5 × (percentile 75 − percentile 25). The length of the lower whisker
corresponds to the minimum non-outside value and the length of the upper whisker is the maximum
non-outside value.
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2.2. Changes in Oral Corticosteroid Dose
During this period, MP consumption progressively decreased in both groups (p < 0.001), but no
inter-group differences were found (p = 0.856), (Figure 2A). Figure 2B shows the progressive increase
in the percentage of patients who were not receiving oral MP during the study (p < 0.001); again, no
differences were observed between groups (p = 0.851). At week 76, mean monthly MP intake was
32.5 ± 66.8 mg in the perennial group and 23.1 ± 46.0 mg in the seasonal group. MP was withdrawn
in 73.9% of patients in the perennial group and in 77.8% in the seasonal group.
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Figure 2. (A) Log-transformation of the oral corticosteroid dose decrease. (B) The progressive increase
in the percentage of patients who were not receiving oral methyl-prednisolone (MP) during the study
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2.3. Changes in Eosinophils, FeNO, and IgE Concentration
Figure 3 shows the changes in eosinophils, FeNO, and IgE concentration.
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Figure 3. Changes in eosinophil count, FeNO and IgE values during follow-up in bo h groups.
(A,B) show the decrease in eosinophils. A non-statistically significant trend towards a decrease in the
absolute number of cells (p = 0.086) was found. Although the difference was not statistically significant,
the seasonal group showed a more marked decrease. FeNO values (C) remained stable along the
follow-up and the IgE concentration (D) initially increased in both groups—as expected—and showed
a trend to stabilize or slightly decrease during follow-up.
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Eosinophils showed a trend towards a decrease in the absolute number of cells (p = 0.086) but not
in percentage (p = 0.251) (Figure 3A,B). The percentage of patients with an eosinophil profile above
300 cells decreased during follow-up: in perennial allergic patients from 57.9% at entry to 52.6% at
week 24 and to 36.8% at week 76 (p = 0.194), and in seasonal patients from 55.6% at entry to 22.2% at
24 weeks, remaining at 22.2% at 76 weeks (p = 0.134) (Figure 4).
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2.4. PFTs Evolu ion
Despite oral MP decrease, PFTs did not deteriorate (Figure 5) in either group. However, the
seasonal allergen patients maintained higher spirometry values (around 200 mL) which, although not
statistically significant, could be considered clinically relevant. FEV1/FVC values were 60.7% ± 13.1%
and 69.1% ± 12.8% for perennial and seasonal patients respectively at entry and 61.3% ± 12.2% and
73.4% ± 11.6% at the end of follow-up.
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2.5. Side Effects
The treatment was well-tolerated and no relevant side effects were detected.
3. Discussion
In November 2006, the GINA [1] later followed by the Guía Española para el Manejo del Asma
GEMA [11] and some other guidelines included a biological treatment for bronchial asthma for the first
time. This treatment was omalizumab, which had shown its clinical efficacy and effectiveness [4–9].
This drug was marketed for severe IgE-mediated asthma patients allergic to a perennial allergen and
was included as add-on therapy in GINA step V asthma patients. Some authors have proposed that
omalizumab may have a wider range of possible prescriptions. Nonetheless, the manufacturer has not
changed the prescription criteria for asthma. The drug is still recommended only for severe asthma
patients allergic to at least one perennial allergen.
Omalizumab has been tested in cases of rhinitis caused by seasonal allergens causing symptoms
during the season of pollination, with great success [12] as well as in perennial allergic rhinitis [13].
Our purpose in the present study was to evaluate whether omalizumab could be as effective in severe
oral corticosteroid-dependent chronic asthma attributed to a seasonal allergen as in patients affected
by a perennial allergen.
We were careful to identify seasonal allergic patients as reliably as possible in order to distinguish
them from perennial allergen patients. We recruited two patients allergic to perennial allergens for
every patient with seasonal allergy. This procedure was chosen to allow a better comparison of the
behavior of the perennial group with that of our previously published cohort [14], which included
32 patients followed up during two years. All patients were oral corticosteroid-dependent and fulfilled
the criteria for omalizumab treatment, except for the fact that one group included sensitization to
seasonal allergens. The rate of non-responders, between 5% and 10%, was in accordance with our
previous experience [14]. The patient sample size was calculated based on our empiric experience since
no previous information was available. We considered a minimum of 10 patients to be representative
if the behavior of the group was homogeneous. Our results showed that both groups had a similar
clinical response to omalizumab.
In the past few years, several attempts have been made to categorize severe asthma into
phenotypes by the application of unsupervised cluster analyses. Apart from allergic asthma, the
most prominent phenotype to emerge is characterized by eosinophilic airway inflammation in spite
of using high-intensity anti-inflammatory treatment [15,16]. About one-third of patients with severe
asthma are considered to have this refractory eosinophilic asthma phenotype [17]. Our cohort of
patients could be included in this group, since all were receiving oral corticosteroids but had a notably
high concentration of eosinophils (> 400 cells and > 5%); these rates were above the ones used in
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the DREAM [16] and MENSA [17] studies for defining patients as eosinophilic and thus eligible for
prescription of an anti-IL5 mAb [18]. In the MENSA study, the geometric mean of eosinophils was 295
cells per microliter [19]. In both our groups, the eosinophil count fell progressively after omalizumab
exposure, though the reduction was more marked after 24 weeks in the seasonal group. Moreover,
the percentage of patients showing the eosinophil profile also decreased notably and with a similar
intensity in both groups. This is not surprising because in the airways of patients with allergic asthma,
the drug reduces FcεRI+ (IgE high affinity receptor) and IgE+ cells and causes a profound reduction in
tissue eosinophilia, together with reductions in submucosal T-cell and B-cell counts [5,20].
FeNO values were mainly normal or quite low, in any case lower than the values found
in the DREAM [18] and MENSA [19] studies. This is probably because all patients were oral
corticosteroid-dependent. The number of overweight or obese patients was also similar, thus ruling
out excess weight as a potential confounding factor.
The behavior of the two groups was quite similar and no statistically significant intergroup
differences were found. The decrease in the year exacerbation rate in both groups despite the decrease
in the oral corticosteroid (OC) consumption endorses the clinical effect of omalizumab toward a better
disease stabilization and control. The only sustained difference was the permanently higher FEV1
value in the seasonal group that, though not statistically significant, was clinically relevant (200 mL at
entry and maintained during the follow-up). This suggests that permanent exposure to allergens may
be more harmful than episodic exposure. The side-effect profile was highly favorable in both groups.
The study has several limitations, the most important being the reduced number of patients and
the lack of a placebo randomized control group. Rather than comparing two different treatments, we
assessed the clinical response to the same treatment in two different populations: patients allergic to
perennial allergens and patients allergic to seasonal allergens. The only way to perform a randomized
study would be to have had a treated and a placebo arm in each group. Considering the impossibility
of preparing a reliable placebo, and the fact that omalizumab is indicated only for patients allergic
to at least one perennial allergen, a study of this kind would have to be done by the pharmaceutical
company. Thus, we believe that our study represents the only way to make this information available
in the literature. Finally, distinguishing between perennial and seasonal patients is extremely complex
although we are confident that we were able to do so. Our discussion, based on our results helps to
make understandable why chronic severe allergic asthma patients sensitized to seasonal allergens can
also benefit from anti-IgE treatment. Since it has been shown in previous studies that sensitization to
different allergens is not associated with significant differences in severity and control of asthma [21]
one could expect similar results regarding treatment.
The results of several large randomized trials have shown that omalizumab is effective and
well-tolerated as an add-on therapy in patients with severe persistent allergic asthma due to perennial
allergen exposure. Omalizumab treatment significantly improves symptoms and disease control,
reduces asthma exacerbations, and increases patients’ quality of life [22]. Our study corroborates
these findings, but also shows that omalizumab is helpful for severe chronic asthma caused by
seasonal allergens.
4. Materials and Methods
4.1. Study Design
In this prospective interventional study performed at the Corporació Sanitària Parc Taulí, a
750-bed university hospital with a reference area of 450,000 inhabitants, two groups of patients with
uncontrolled severe oral corticosteroid dependent allergic asthma were treated with the same drug,
omalizumab. The study was approved by the hospital’s ethics committee (CEIC/CEIm Institut
d'Investigació i Innovació Parc Taulí-2017/527). Since the treatment for asthma attributed to a seasonal
allergen was an off-label indication, its use was considered as compassionate; in accordance with the
Spanish legislation, written informed consent was obtained in these patients.
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4.2. Population
Eligible patients met the ERS/ATS criteria for a diagnosis of severe asthma; all had stable treatment
requirements of at least 1000 µg fluticasone propionate with 100 µg of salmeterol or equivalent.
Patients were considered to be corticosteroid-dependent when they required a minimum of 4 mg
of methyl-prednisolone (MP) per day ≥1 year or boosters of MP equivalent to a mean daily dose
of 4 mg of MP. Participants had to maintain their treatment (standard of care) throughout the study.
Exclusion criteria included past or present smoking, substantial uncontrolled comorbidity, possibility
of pregnancy, and history of poor treatment adherence.
Uncontrolled asthma was defined according to the ERS/ATS criteria [23]. Patients had to follow
any one of the following criteria: frequent severe exacerbations (two or more bursts of systemic oral
corticosteroids (OCs) (>3 days each) in the previous year or requiring to double their baseline dose of
OCs); serious exacerbations: at least one hospitalization, Intensive Care Unit stay or mechanical
ventilation in the previous year; airflow limitation: FEV1 < 80% predicted (in the presence of
reduced FEV1/FVC defined as less than the lower limit) following a withhold of both short-and
long-acting bronchodilators.
We classified patients into two groups: (a) those with asthma due to seasonal allergens, and
(b) those with asthma due to perennial allergens. In both situations, a cause-effect relationship had to
be clinically established. For each patient with asthma due to seasonal allergens, we recruited the next
two consecutive patients with asthma due to perennial allergens. The criteria used to discern the type
of allergen causing the asthma were the following: (a) when a single perennial allergen was involved
(dust mites or moulds), the asthma was considered to be caused by a perennial allergen; (b) When the
single allergen was a pollen, and the hospital patient’s folder revision revealed that the asthma showed
seasonal symptoms at the beginning, the asthma was considered seasonal; (c) in cases in which both
seasonal and perennial allergen sensitization was detected, in patients sensitized to epithelia at the
time of the first skin prick tests, we made all possible efforts to ensure that exposure was stopped.
In addition to the clinical information at the hospital we reviewed the electronic medical records of
patients in which the primary care physician had documented the absence of animal exposure. In case
of doubt, we personally contacted the patient's primary care physician. Thus, although persisting, this
sensitization was considered irrelevant to disease’s evolution. All patients with pollen seasonal allergy
had perennial symptoms before the appearance of house dust mite sensitization.
Non-responders were those patients in which omalizumab did not allow a decrease in the number
of exacerbations and/or oral corticosteroid consumption.
The primary outcomes were the oral corticosteroid-sparing effect of omalizumab and the rate
of exacerbations. The secondary variables were changes in pulmonary function tests (PFTs) and the
exhaled fraction of nitric oxide (FeNO). The safety outcome was the reporting of side effects.
4.3. Size Calculation
We planned to recruit a minimum of ten patients in the seasonal group. For each patient with
asthma due to a seasonal allergen, we recruited the next two consecutive patients with asthma due to
a perennial allergen that fulfilled the criteria. We assumed a loss of 10% in each group.
4.4. Procedures
(a) A skin prick test was performed in every patient (ALK-Abello® testing allergens); (b) The test
was considered positive when the reaction was ≥ to histamine and ≥3 mm; (c) Omalizumab dose was
calculated according to the Novartis® dosing table based on IgE concentration and patient's weight.
Depending on the total dose, the drug was administered subcutaneously, either bi-weekly or monthly;
(d) Patients were considered responders or non-responders after 24 weeks of omalizumab treatment;
(e) The dose of oral MP was tapered at a rate of 2 mg every two weeks depending on tolerance, as in
previous studies [4,14]; (f) At each monthly visit, a forced spirometry and FeNO measurement were
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performed and the accumulated monthly MP dose was calculated; (g) The follow-up lasted 76 weeks;
(h) Side-effects were investigated at each outpatient visit.
4.5. Statistical Analysis
Descriptive analysis was performed using central tendency and dispersion measures for
continuous variables and the distribution of frequencies for categorical variables. Depending on
the variable distribution, t-test, Wilcoxon rank-sum, or Fisher’s exact test was used to analyze the
homogeneity between groups. Linear mixed-models with two levels (subject and visit) were fitted
to analyze the evolution of the different parameters of interest over time. Because the distributions
of residuals of corticoids, FeNO and IgE were skewed, data were log-transformed for analysis. In all
cases, a p score less than 0.05 was considered statistically significant. Software STATA version 11.2
(Stata Corp., College Station, TX, USA) was used.
5. Conclusions
These findings have two direct implications, one pathophysiological and one clinical. From the
pathophysiological point of view, we can now confirm that it is the presence of the IgE that causes
the persistence of the allergic cascade, and that allergens are merely a trigger factor. This would
at least be proven in case of asthma due to seasonal allergens. In case of perennial allergens, the
continuous exposure to the allergen precludes us extending this conclusion to this group. The clinical
implication is that omalizumab prescription should be extended to severe asthma patients allergic to
seasonal allergens.
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